ArticleBMC urology2025
Clinical analysis of percutaneous kidney-sparing surgery for upper tract urothelial carcinoma.
Article in BMC urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo analyze and summarize the clinical and pathological characteristics and prognosis of percutaneous kidney-sparing surgery (PCKSS) for the treatment of upper tract urothelial carcinoma (UTUC).
methodsA retrospective analysis was conducted on the clinical data and oncological characteristics of 16 cases of UTUC with PCKSS admitted to the Urology Department of Peking University Third Hospital from July 2015 to December 2023, and postoperative follow-up was conducted on the patients. All cases were discussed at a multi-disciplinary treatment group and underwent PCKSS by the same surgeon.
resultsAs a result, all 16 cases of PCKSS surgery were successfully completed, with 3 cases having multiple tumors. The median surgical time is 150 (75–216) minutes, and the median intraoperative bleeding volume is 150 (20–800) ml. Postoperative pathological diagnosis showed 11 cases of high-grade urothelial carcinoma and 10 cases in pTa. The average postoperative hospitalization time is 7.2 ± 2.2 days. During a median follow-up of 22 (2–93) months, 7 cases of recurrence and 2 cases of death due to tumors.
conclusionPCKSS is a minimally invasive surgical method for the treatment of UTUC, which avoids serious complications caused by radical surgery. However, it is necessary to carefully select suitable patients before surgery, and strict and regular follow-up is required after surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.